RPTX — Repare Therapeutics Share News
0.000.00%
Last trade - 00:00- $112.94m
- $0.34m
- $53.48m
Repare Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Repare Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview
Brief: Repare Therapeutics Provides Business Update And Reports Second Quarter 2022 Financial Results
Repare Therapeutics jumps on licensing pact with Roche
Brief: Repare Therapeutics Inc Entered Into A Collaboration And License Agreement With Hoffmann-La Roche Inc. And F. Hoffmann-La Roche Ltd
Brief: Repare Therapeutics Provides Business Update And Reports First Quarter 2022 Financial Results
Brief: Repare Therapeutics Announces Publication Of Preclinical Data in Nature Demonstrating Potential of RP-6306 In Tumors With CCNE1 Amplification
Repare Therapeutics rises after 'promising' cancer drug data
Brief: Repare Therapeutics Presents Updated Clinical Data From Ongoing Phase 1/2 TRESR Study Of RP-3500 Monotherapy In Solid Tumors
Brief: Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data From The Phase 1/2 TRESR Clinical Trial At The 2022 ESMO Targeted Anticancer Therapies Congress
Repare Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Repare Therapeutics Provides Business Update And Reports Fourth Quarter And Full Year 2021 Financial Results
Repare Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: Repare Therapeutics Estimates Cash, Cash Equivalents As Of Dec 31, 2021 About $341.7 Mln
Brief: Repare Therapeutics Provides Corporate Update And Highlights Key Milestones Anticipated In 2022
Brief: Repare Therapeutics Doses First Patient In Phase 1 Clinical Trial Of RP-6306 In Combination With Gemcitabine
Repare Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Repare Therapeutics Provides Business Update And Reports Third Quarter 2021 Financial Results
Brief: Repare Therapeutics Announces Pricing Of Upsized Offering Of Common Shares